GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (LTS:0W4N) » Definitions » EV-to-EBITDA

Formycon AG (LTS:0W4N) EV-to-EBITDA : -90.42 (As of Apr. 28, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Formycon AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Formycon AG's enterprise value is €370.62 Mil. Formycon AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €-4.10 Mil. Therefore, Formycon AG's EV-to-EBITDA for today is -90.42.

The historical rank and industry rank for Formycon AG's EV-to-EBITDA or its related term are showing as below:

LTS:0W4N' s EV-to-EBITDA Range Over the Past 10 Years
Min: -445.66   Med: -56.6   Max: 131.71
Current: -90.42

During the past 13 years, the highest EV-to-EBITDA of Formycon AG was 131.71. The lowest was -445.66. And the median was -56.60.

LTS:0W4N's EV-to-EBITDA is ranked worse than
100% of 508 companies
in the Biotechnology industry
Industry Median: 7.41 vs LTS:0W4N: -90.42

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-04-28), Formycon AG's stock price is €23.00. Formycon AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-7.180. Therefore, Formycon AG's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Formycon AG EV-to-EBITDA Historical Data

The historical data trend for Formycon AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG EV-to-EBITDA Chart

Formycon AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.89 -50.41 34.42 11.20 -221.20

Formycon AG Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.42 - 11.20 - -221.20

Competitive Comparison of Formycon AG's EV-to-EBITDA

For the Biotechnology subindustry, Formycon AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Formycon AG's EV-to-EBITDA falls into.


;
;

Formycon AG EV-to-EBITDA Calculation

Formycon AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=370.619/-4.099
=-90.42

Formycon AG's current Enterprise Value is €370.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Formycon AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €-4.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Formycon AG  (LTS:0W4N) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Formycon AG's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=23.00/-7.180
=At Loss

Formycon AG's share price for today is €23.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Formycon AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-7.180.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Formycon AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Formycon AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Formycon AG Headlines

No Headlines